These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10160489)

  • 41. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company.
    Burckel E; Ashraf T; de Sousa Filho JP; Forleo Neto E; Guarino H; Yauti C; Barreto F de B; Champion L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):563-76. PubMed ID: 10662481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opening and continuing the discussion on influenza vaccination timing.
    Ryan KJ; Rousculp MD
    Am J Manag Care; 2010 Aug; 16(8):628-9; author reply 629-30. PubMed ID: 20737745
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost-Effectiveness Analysis of a Television Campaign to Promote Seasonal Influenza Vaccination Among the Elderly.
    Kim M; Yoo BK
    Value Health; 2015 Jul; 18(5):622-30. PubMed ID: 26297090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population-wide benefits of routine vaccination of children against influenza.
    Weycker D; Edelsberg J; Halloran ME; Longini IM; Nizam A; Ciuryla V; Oster G
    Vaccine; 2005 Jan; 23(10):1284-93. PubMed ID: 15652671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.
    Pradas-Velasco R; Antoñanzas-Villar F; Martínez-Zárate MP
    Pharmacoeconomics; 2008; 26(1):45-56. PubMed ID: 18088158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Socioeconomics of influenza and influenza vaccination in Europe.
    Nicholson KG
    Pharmacoeconomics; 1996; 9 Suppl 3():75-8. PubMed ID: 10160492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.
    Nichol KL; Goodman M
    Pharmacoeconomics; 1999; 16 Suppl 1():63-71. PubMed ID: 10623378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea.
    Suh J; Kim B; Yang Y; Suh DC; Kim E
    Vaccine; 2017 May; 35(21):2811-2817. PubMed ID: 28427844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Real-time monitoring of anti-influenza vaccination in the 65 and over population in France based on vaccine sales].
    Pivette M; Auvigne V; Guérin P; Mueller JE
    Rev Epidemiol Sante Publique; 2017 Apr; 65(2):119-124. PubMed ID: 28190629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients.
    Wongsurakiat P; Lertakyamanee J; Maranetra KN; Jongriratanakul S; Sangkaew S
    J Med Assoc Thai; 2003 Jun; 86(6):497-508. PubMed ID: 12924797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cost of influenza in Thailand.
    Simmerman JM; Lertiendumrong J; Dowell SF; Uyeki T; Olsen SJ; Chittaganpitch M; Chunsutthiwat S; Tangcharoensathien V
    Vaccine; 2006 May; 24(20):4417-26. PubMed ID: 16621187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic analysis of pandemic influenza vaccination strategies in Singapore.
    Lee VJ; Tok MY; Chow VT; Phua KH; Ooi EE; Tambyah PA; Chen MI
    PLoS One; 2009 Sep; 4(9):e7108. PubMed ID: 19771173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cost-effectiveness of influenza vaccination The Netherlands].
    Reinders A; Postma MJ; Govaert TM; Sprenger MJ
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):93-7. PubMed ID: 9036354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic and social impact of epidemic and pandemic influenza.
    Vaccine; 2006 Nov; 24(44-46):6776-8. PubMed ID: 17167882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic review of economic evaluations of seasonal influenza vaccination for the elderly population in the European Union.
    Shields GE; Elvidge J; Davies LM
    BMJ Open; 2017 Jun; 7(6):e014847. PubMed ID: 28601824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical economics in the field of influenza--past, present and future.
    Szucs TD
    Virus Res; 2004 Jul; 103(1-2):25-30. PubMed ID: 15163484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influenza--the forgotten vaccination.
    Martin DJ; Schoub BD
    S Afr Med J; 1997 Jul; 87(7):869-71. PubMed ID: 9259719
    [No Abstract]   [Full Text] [Related]  

  • 60. Influenza vaccine for healthy adult workers: an issue for health authorities or employers?
    Garattini L; Koleva D
    Health Policy; 2011 Sep; 102(1):89-95. PubMed ID: 21093952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.